1
|
Abstract
The renin-angiotensin system (RAS) has been recognized for many years as critical pathway for blood pressure control and kidney functions. Although most of the well-known cardiovascular and renal effects of RAS are attributed to angiotensin-converting enzyme (ACE), much less is known about the function of ACE2. Experiments using genetically modified mice and inhibitor studies have shown that ACE2 counterbalances the functions of ACE and that the balance between these two proteases determines local and systemic levels of RAS peptides such as angiotensin II and angiotensin1-7. Ace2 mutant mice exhibit progressive impairment of heart contractility at advanced ages, a phenotype that can be reverted by loss of ACE, suggesting that these enzymes directly control heart function. Moreover, ACE2 is also found to be upregulated in failing hearts. In the kidney, ACE2 protein levels are significantly decreased in hypertensive rats, suggesting a negative regulatory role of ACE2 in blood pressure control. Moreover, ACE2 expression is downregulated in the kidneys of diabetic and pregnant rats and ACE2 mutant mice develop late onset glomerulonephritis resembling diabetic nephropathy. Importantly, ACE2 not only controls angiotensin II levels but functions as a protease on additional molecular targets that could contribute to the observed in vivo phenotypes of ACE2 mutant mice. Thus, ACE2 seems to be a molecule that has protective roles in heart and kidney. The development of drugs that could activate ACE2 function would allow extending our treatment options in diabetic nephropathy, heart failure, or hypertension.
Collapse
Affiliation(s)
- Ursula Danilczyk
- IMBA, Institute for Molecular Biotechnology, Austrian Academy of Sciences, D. Bohr Gasse 7, A-1030 Vienna, Austria
| | | |
Collapse
|
2
|
Gerlofs-Nijland ME, Assmann KJM, Dijkman HBPM, Dieker JWC, van Son JPHF, Mentzel S, van Kats JP, Danser AHJ, Smithies O, Groenen PJTA, Wetzels JFM. Albuminuria in mice after injection of antibodies against aminopeptidase A: role of angiotensin II. J Am Soc Nephrol 2001; 12:2711-2720. [PMID: 11729240 DOI: 10.1681/asn.v12122711] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
It has been shown that injection of combinations of anti-aminopeptidase A (APA) monoclonal antibodies (mAb) that inhibit the enzyme activity induces an acute albuminuria in mice. This albuminuria is not dependent on inflammatory cells, complement, or the coagulation system. APA is an important regulator of the renin-angiotensin system because it is involved in the degradation of angiotensin II (Ang II). This study examined the potential role of glomerular Ang II in the induction of albuminuria. The relation among renal Ang II, glomerular APAX enzyme activity, and albuminuria was examined first. Injection of the nephritogenic combinations ASD-3/37 and ASD-37/41 in BALB/c mice induced albuminuria, whereas the non-nephritogenic combination ASD-3/41 had no effect. There was no clear relation between the inhibition of glomerular APA activity and albuminuria, yet it was evident that intrarenal Ang II levels were significantly increased in albuminuric mice and not in nonalbuminuric mice. As a next step, anti-APA mAb were administered to angiotensinogen-deficient mice that do not produce Ang II, and kidney morphology and albuminuria were determined. Angiotensinogen-deficient mice also developed albuminuria upon ASD-37/41 administration. Altogether, these findings clearly demonstrate that Ang II is not required for the induction of albuminuria upon injection of enzyme-inhibiting anti-APA mAb.
Collapse
Affiliation(s)
- Miriam E Gerlofs-Nijland
- Departments of *Pathology and †Internal Medicine, Division of Nephrology, University Medical Centre Nijmegen, Nijmegen, and Departments of Internal Medicine and Pharmacology, Cardiovascular Research Institute Erasmus University Rotterdam (COEUR), Rotterdam, The Netherlands; and Department of Pathology, University of North Carolina, Chapel Hill, North Carolina
| | - Karel J M Assmann
- Departments of *Pathology and †Internal Medicine, Division of Nephrology, University Medical Centre Nijmegen, Nijmegen, and Departments of Internal Medicine and Pharmacology, Cardiovascular Research Institute Erasmus University Rotterdam (COEUR), Rotterdam, The Netherlands; and Department of Pathology, University of North Carolina, Chapel Hill, North Carolina
| | - Henry B P M Dijkman
- Departments of *Pathology and †Internal Medicine, Division of Nephrology, University Medical Centre Nijmegen, Nijmegen, and Departments of Internal Medicine and Pharmacology, Cardiovascular Research Institute Erasmus University Rotterdam (COEUR), Rotterdam, The Netherlands; and Department of Pathology, University of North Carolina, Chapel Hill, North Carolina
| | - Jürgen W C Dieker
- Departments of *Pathology and †Internal Medicine, Division of Nephrology, University Medical Centre Nijmegen, Nijmegen, and Departments of Internal Medicine and Pharmacology, Cardiovascular Research Institute Erasmus University Rotterdam (COEUR), Rotterdam, The Netherlands; and Department of Pathology, University of North Carolina, Chapel Hill, North Carolina
| | - Jacco P H F van Son
- Departments of *Pathology and †Internal Medicine, Division of Nephrology, University Medical Centre Nijmegen, Nijmegen, and Departments of Internal Medicine and Pharmacology, Cardiovascular Research Institute Erasmus University Rotterdam (COEUR), Rotterdam, The Netherlands; and Department of Pathology, University of North Carolina, Chapel Hill, North Carolina
| | - Stef Mentzel
- Departments of *Pathology and †Internal Medicine, Division of Nephrology, University Medical Centre Nijmegen, Nijmegen, and Departments of Internal Medicine and Pharmacology, Cardiovascular Research Institute Erasmus University Rotterdam (COEUR), Rotterdam, The Netherlands; and Department of Pathology, University of North Carolina, Chapel Hill, North Carolina
| | - Jorge P van Kats
- Departments of *Pathology and †Internal Medicine, Division of Nephrology, University Medical Centre Nijmegen, Nijmegen, and Departments of Internal Medicine and Pharmacology, Cardiovascular Research Institute Erasmus University Rotterdam (COEUR), Rotterdam, The Netherlands; and Department of Pathology, University of North Carolina, Chapel Hill, North Carolina
| | - A H Jan Danser
- Departments of *Pathology and †Internal Medicine, Division of Nephrology, University Medical Centre Nijmegen, Nijmegen, and Departments of Internal Medicine and Pharmacology, Cardiovascular Research Institute Erasmus University Rotterdam (COEUR), Rotterdam, The Netherlands; and Department of Pathology, University of North Carolina, Chapel Hill, North Carolina
| | - Oliver Smithies
- Departments of *Pathology and †Internal Medicine, Division of Nephrology, University Medical Centre Nijmegen, Nijmegen, and Departments of Internal Medicine and Pharmacology, Cardiovascular Research Institute Erasmus University Rotterdam (COEUR), Rotterdam, The Netherlands; and Department of Pathology, University of North Carolina, Chapel Hill, North Carolina
| | - Patricia J T A Groenen
- Departments of *Pathology and †Internal Medicine, Division of Nephrology, University Medical Centre Nijmegen, Nijmegen, and Departments of Internal Medicine and Pharmacology, Cardiovascular Research Institute Erasmus University Rotterdam (COEUR), Rotterdam, The Netherlands; and Department of Pathology, University of North Carolina, Chapel Hill, North Carolina
| | - Jack F M Wetzels
- Departments of *Pathology and †Internal Medicine, Division of Nephrology, University Medical Centre Nijmegen, Nijmegen, and Departments of Internal Medicine and Pharmacology, Cardiovascular Research Institute Erasmus University Rotterdam (COEUR), Rotterdam, The Netherlands; and Department of Pathology, University of North Carolina, Chapel Hill, North Carolina
| |
Collapse
|